2002, Number S1
<< Back Next >>
Arch Cardiol Mex 2002; 72 (S1)
Septal ablation in the treatment of hypertrophic cardiomyopathy
Ban HE
Language: Spanish
References: 15
Page: 18-21
PDF size: 53.98 Kb.
ABSTRACT
Hypertrophic cardiomyopathy is a relative frequent disease and probably the most common genetic transmitted cardiovascular disease. Fortunately, the more aggressive varieties of the disease represent the less common manifestation of it. Outflow left ventricular obstruction is present in about 25 to 30% of the cases. Recently, septal ablation by means of the selective alcohol injection in left anterior descendent septal branches was introduced as a therapeutic alternative in cases associated with left ventricular outflow obstruction. Results with this technique have been encouraging with a success rate over 90%, and a low rate incidence of complications and mortality. These results are similar to those of surgical myectomy. We review indications, technique, and results obtained with this procedure.
REFERENCES
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O ‘Connell J, et al: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842.
Maron BJ, Gardin FJ, Flack JM, Gidding SS, Bild D: Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995; 92: 785-89.
Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997; 350: 127-33.
Henry WL, Clark GE, Griffith JM Epstein SE: Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hvpertrophy (idiopatic hypertrophic subaortic stenosis). Am J Cardiol 1975; 35: 337-45.
Wigle ED, Rakowski H, Kimball BP, Williams WG: Hypertrophc cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92: 1680-1692.
Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
Sigwart U, Gribc M, Essinger A, Rivier JL: L’effet aigu d’une occlusion coronarienne par ballonet de la dilatation transluminale. Schweiz Med Wochenschr 1982; 45: 1631 (Abstr).
Sigwart U, Grbic M, Payor M, Essinger A, Sadeghi H: Wall motion during balloon occlusion. Sigwart U, Heintzen PH. eds. Ventricular wall motion. New York Georg. Thieme, 1983: 206-10.
Gietzen F, Leuner C, Gerenkamp T, Jun H: Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal branch of the left coronary artery. Eur Heart (Abstr) 1994; 15: 125.
Faber L, Seggewiss H, Gleichmann U: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial constrast echocardiography. Circulation. 1998; 98: 24152421.
Lakkis N, Nagueh SF, Kleiman NS, Killip D, Zuo-Xiang He, Verani MS et al: Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998; 98: 1750-1755.
Gietzen FH, Leuner CHJ, Hegselmann J, Strunk-Mueller C, Khun H: Acute and long-term results after TASH. Letters to the Editor. A reply. Eur Heart J 2000; 21: 591-93.
Ruzyllo W, Chojnowska L, Demkow M, Witowski A, Kusmierczyk B, Piotrowski W, et al: Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 770-777.
Seggewiss H: Percutaneous transluminal septal myocardial ablation: A new treatment for hvpertrophic obstructive cardiomyopathy. (Editorial). Eur Heart J 2000; 21: 704-707.
Roberts R, Sigwart U: New Concepts in Hypertrophic Cardiomyopathies. Part II. Circulation 2001; 104: 2249-2252.